It was used. Now first line is letrozole
For oligo-ovulatory women with PCOS undergoing ovulation induction, we now suggest letrozole as first-line therapy over clomiphene citrate, regardless of the patient’s BMI. Before starting letrozole, the clinician must discuss that this use of the drug is not approved by the US Food and Drug Administration (FDA) for this purpose and that there is an available alternative (clomiphene citrate).
removing indication for PCOS and approving